Navigation Links
Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
Date:4/9/2012

(WASHINGTON, April 9, 2012) A novel anti-leukemia compound with little toxicity successfully treated zebrafish with T-cell acute lymphoblastic leukemia (T-ALL), suggesting its potential to become a new highly targeted therapy for humans even those resistant to conventional therapies according to results from a study published online today in Blood, the Journal of the American Society of Hematology (ASH).

T-ALL is a cancer of the white blood cells in which genetic mutations cause normal immature T-cells to develop into leukemic cells, or "blasts." These blasts then quickly build up and crowd out normal cells, spreading into the bloodstream and other areas of the body and creating life-threatening symptoms, including excessive bleeding and frequent infections.

Despite major advances made in leukemia treatment particularly multi-agent chemotherapy over the last 50 years, chemotherapy remains highly toxic because it attacks both cancerous and normal cells. In addition, patients with T-ALL who relapse typically have a very poor prognosis, underscoring the need for more targeted therapies to combat the high toxicity and mortality associated with current T-ALL treatment.

Because normal immature T-cells and T-ALL blasts share common development and cell activation pathways, Nikolaus Trede, MD, PhD, Associate Professor of Pediatrics and investigator at the Huntsman Cancer Institute at the University of Utah, and colleagues hypothesized that T-ALL treatments that specifically eliminate one may also target the other. To test their hypothesis, Dr. Trede's team turned to an entirely different species zebrafish to identify a compound that could pack an anti-leukemic punch.

"Zebrafish serve as an excellent model for many cancers, including leukemia, because the zebrafish and human genomes and immune systems share many similarities, making them easy targets for genetic modification to mimic human cancers," said Dr. Trede, the study's senior author.

Dr. Trede's team used a line of zebrafish they had previously created, in which immature T-cells were fluorescently labeled so they effectively "glowed" when present, to help identify whether any test compound eliminated those cells while ensuring that they did not affect any other cell types or compromise the overall health of the fish. They screened 26,400 molecules and identified the novel molecular compound Lenaldekar (LDK) as effective in eliminating immature zebrafish T-cells and targeting human T-ALL cell lines without causing major toxicity to other cell types.

After confirming LDK's effectiveness in vitro, the investigators then tested its efficacy in zebrafish and mouse models of human T-ALL. After a 14-day treatment period, researchers found that more than 60 percent of all zebrafish treated with LDK maintained long-term remission (more than nine months), while 100 percent of zebrafish treated with the control died by day 40. Similarly, in the mouse model, treatment with LDK significantly slowed disease progression without toxicity.

The team then examined LDK's effectiveness in treating cells taken directly from patients with other leukemias, namely chronic myeloid leukemia (CML) and B-cell ALL (B-ALL), including those resistant to current therapies. After testing a number of patient samples, researchers found that LDK was active against the vast majority of primary leukemia samples, demonstrating its effectiveness beyond T-ALL.

In addition to demonstrating LDK's efficacy, investigators also discovered that the compound works differently from current leukemia treatments because it inhibits both an important signaling pathway that promotes the survival of leukemia cells and a pathway that controls the cell division process, disrupting the proliferation of leukemic cells and, in essence, leading to their self-induced death. Because of this unusual combination of effects, this study positions LDK as a more selective, less-toxic option than current therapies.

"This is the first successful approach using zebrafish larvae to identify molecules with potency against leukemia from a small molecular library containing compounds with unknown activity," said Dr. Trede. "We are encouraged by LDK's path from a virtual unknown to a potential powerhouse against leukemia, and we are working on discovery of LDK's cellular target, which may ultimately help convert the compound into a drug that can be used in patients with leukemia."


'/>"/>

Contact: Claire Gwayi-Chore
cgwayi-chore@hematology.org
202-776-0544
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. Novel drug in pill form safer than standard approach to treat blocked lung blood vessels
2. Novel mouse model for autism yields clues to a 50-year-old mystery
3. Unprecedented academic-industry collaboration seeks new drugs and novel treatments for autism
4. Novel plastics and textiles from waste with the use of microbes
5. UC San Diego among first in nation to treat brain cancer with novel viral vector
6. Students at Western University develop a novel way to teach interdisciplinary care
7. UH Case Medical Center publishes study on novel treatment for skin lymphoma
8. Mass. General researchers find novel way to prevent drug-induced liver injury
9. Rutgers, Massachusetts General investigators find novel way to prevent drug-induced liver injury
10. NIH scientists identify novel approach to view inner workings of viruses
11. Novel Stem Cell Treatment May Hold Promise for Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... A revolution is underway. Brooklyn-based ... experience for the millions of people who require these medical transport services annually. ... through the use of technology. Now, SmartEMS has put forth an industry-changing app ...
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
Breaking Medicine Technology: